title: Ofatumumab for rituximab-resistant nephrotic syndrome.
authors.affiliation: Nil Ratan Sircar Medical College and Hospital, Kolkata, India basuv3000@gmail.com.
authors.forename: Biswanath
authors.initials: B
authors.lastname: Basu
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000419:Albuminuria / Q000652:urine; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D016559:Tacrolimus / Q000627:therapeutic use; D028761:Withholding Treatment
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; C527517:ofatumumab; D016559:Tacrolimus